From the Departments of Dermatology, Academisch Medisch Centrum, Amsterdam, the Netherlands (Drs Zonneveld and Bos), Latvian Medical Academy, Riga (Dr Rubins), Albert Szent-Györgyi Medical University, Szeged, Hungary (Dr Dobozy), Heinrich Heine University, Düsseldorf, Germany (Dr Ruzicka), Ludwig Maximilians University, Munich, Germany (Dr Kind), Hôpital St Louis, Paris, France (Dr Dubertret), and Klinika Dermatologiczna, Warsaw, Poland (Dr Jablonska).
Cyclosporine for the treatment of psoriasis constitutes a new approach. Alternative systemic cyclosporine derivatives have been studied to find an immunosuppressive drug with fewer adverse effects. Tacrolimus is one of these new immunosuppressive drugs. Systemically, it has been proven effective in treating psoriasis. A topical formulation of tacrolimus is attractive because it has fewer adverse effects and is useful for a large group of patients. We report for the first time on the efficacy of nonocclusive topical tacrolimus in the treatment of psoriasis.
After a washout phase of 2 weeks, patients were randomized to receive 0.005% calcipotriol ointment twice daily, placebo ointment once daily, or 0.3% tacrolimus ointment once daily. One psoriatic plaque was treated with a surface area of 40 to 200 cm2. Efficacy was estimated using the local psoriasis severity index. The reduction in the local psoriasis severity index score after 6 weeks was 62.5% in the calcipotriol group, 33.3% in the tacrolimus group, and 42.9% in the placebo group.
There was no statistically significant difference between the efficacy of tacrolimus and placebo ointment (P=.77). Calcipotriol ointment, applied twice daily, had a better effect than tacrolimus ointment and placebo ointment once daily.
THE INTRODUCTION of systemic immunosuppressive therapy with cyclosporine 1 for psoriasis forms a new approach in its treatment. Cyclosporine has also been found to be useful in other dermatological diseases, such as atopic dermatitis, lichen planus, and pyoderma gangrenosum. Alternative systemic cyclosporine derivatives have been studied to find an immunosuppressive drug with fewer adverse effects, ie, hypertension and nephrotoxicity. Oxeclosporine has been found to be effective in the treatment of psoriasis2 but was later found to have potential hepatotoxic effects (unpublished data, European Study Group, 1992), and thus was not further developed. Another promising drug is systemic tacrolimus. After initial uncontrolled studies,3 a placebo-controlled study was conducted by the European Study Group.4 When given systemically, tacrolimus was found to be effective in treating patients with psoriasis.
For dermatology, a topical formulation of these macrolactam-type cyclic immunosuppressive drugs is an interesting pharmaceutical option. The first studies with topical tacrolimus were performed in 1987.5 Topical tacrolimus was not effective, either in psoriasis or in allergic or atopic eczema.6,7 The ascomycine derivative ASM 281-2408 has also been used topically under occlusion in psoriasis, with promising results. However, a confirmatory study has not been published. Topical tacrolimus was studied in atopic eczema and contact allergy, where it has been successful.9- 12 Topical tacrolimus also has been studied under occlusion on descaled psoriatic skin in microplaques, and in this model topical tacrolimus showed efficacy.13
We have studied the possible efficacy of topical tacrolimus in psoriasis in a 3-armed study for 6 weeks.
After a washout phase of 2 weeks, patients were randomized to receive 0.005% calcipotriol ointment twice daily, placebo ointment (ointment base free of tacrolimus) once daily, or 0.3% tacrolimus ointment once daily. The study was double-blinded except for the calcipotriol group for whom the investigator was not blinded because of the instruction to use the medication twice daily. Only 1 psoriatic plaque with a surface area of 40 to 200 cm2 was treated. Efficacy was estimated using a modified psoriasis area and severity index adjusted for 1 lesion, the local psoriasis severity index (LPSI). The minimum LPSI score was 6.0 at entry.
Seventy patients were studied: 23 in the calcipotriol group, 24 in the tacrolimus group, and 23 in the placebo group. At baseline, patients in the tacrolimus and calcipotriol groups had a median LPSI score of 7.0, and the median LPSI score in the placebo group was 8.0. After 6 weeks, the LPSI score decreased by 33.3% in the tacrolimus group, 62.5% in the calcipotriol group, and 42.9% in the placebo group. There was no statistically significant difference (P=.77) between the efficacy of tacrolimus and placebo ointment. The difference between calcipotriol and tacrolimus ointment was statistically significant, as estimated by the 2-tailed Mann-Whitney test (P<.005).
This study shows that the tacrolimus ointment, when used once daily, was not better than a placebo ointment for the treatment of psoriatic plaques. The study also shows that calcipotriol ointment, used twice daily, had a better effect than tacrolimus ointment and placebo ointment used once daily. Because the effect of a placebo ointment used twice daily was not studied here, it is incorrect to conclude from this study that calcipotriol ointment is superior to placebo or tacrolimus ointment. It should be noted that this was a pilot study with relatively small numbers of patients and only indicates a direction.
Tacrolimus is a 822.05-d molecule that appears to be effective in atopic eczema but not in psoriasis when used as a topical drug. This result might be explained by assuming that the molecular weight prevents penetration into psoriatic skin. Systemic tacrolimus is effective in treating psoriasis. Because of a probable skin barrier defect, molecules with a molecular weight between 800 and 1200 d can penetrate the skin and thus are effective in treating atopic eczema. Furthermore, it is striking that all cyclic topical immunosuppressive drugs have a molecular weight greater than 800 d. Both corticosteroids (mean molecular weight around 450 d) and calcipotriol (molecular weight, 413 d), the 2 drugs that have been proven to be effective in psoriasis, have molecular weights less than 500 d. Until now the only exceptions to the 500-d barrier hypothesis are the studies with oxyclosporine (SDZ 281-240) by Rappersberger et al8 and the study with topical tacrolimus by Remitz et al,13 in which these macrolactams with a molecular weight slightly greater than 800 d were found to have an effect on psoriasis. The efficacy might be related to the occlusive effect of the Finn chambers used in these studies. If a topical formulation could be designed that will enhance penetration in psoriatic skin by first disrupting the skin barrier function, macrolactam-type cyclic immunosuppressive drugs probably would be effective in a topical formulation. Another option is the development of cyclic immunosuppressant drugs with a lower molecular weight.
Accepted for publication June 6, 1998.
This study was sponsored by Fujisawa GmbH, Munich, Germany.
Reprints: I. M. Zonneveld, MD, Department of Dermatology, Academisch Medisch Centrum, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, the Netherlands.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 92
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.